Sensitization of chemotherapy by anti-HER

Breast Cancer

Volumn 11, Issue 2, 2004, Pages 105-115

  Kataoka, Akemi ^a   Ishida, Mayumi ^a   Murakami, Shigeru ^a   Ohno, Shinji ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Breast cancer; Clinical trial; HER2; Monoclonal antibody; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; PHYSIOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 16544363720     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02968288     Document Type: Review

References (50)

1. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M, Vogel C: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002. (Pubitemid 34111379)
2. Slamon D J, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001. (Pubitemid 32222155)
3. Piccart MJ: Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. Ann Oncol 12:89-94, 2001.
4. Ligibel JA, Winer EP: Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Onco129:38-43, 2002. (Pubitemid 34816064)
5. Arteaga CL, Moulder SL, Yakes FM: HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Onco129:4-10, 2002. (Pubitemid 34816060)
6. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D: Inhibitory effects of combinations of HER-2/ neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999. (Pubitemid 29186925)
7. Pegram MD, Lopez A, Konecny G, Slamon DJ: Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 27:21-25; discussion 92-100, 2000. (Pubitemid 32172252)
8. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ, Fendly BM, Chazin VR, Howell SB: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235-2249, 1998. (Pubitemid 28515376)
9. Nahta R, Esteva FJ, Trent S, Yang C, Schmidt EV, Hortobagyi GN, Iglehart JD, Kempkes B: HER-2-targeted therapy: Lessons learned and future directions. Clin Cancer Res 9:5078-5084, 2003. (Pubitemid 37413555)
10. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996.
11. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999. (Pubitemid 29415219)
12. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Onco119:2587-2595, 2001. (Pubitemid 32441364)
13. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P: Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Onco121:3965-3971, 2003. (Pubitemid 46606210)
14. Leyland-Jones B: Dose scheduling-Herceptin. Oneology 61:31-36, 2001.
15. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN: Phase 11 study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Onco120:1800-1808, 2002. (Pubitemid 34273269)
16. Montemurro F, Choa G, Faggiuolo R, Sperti E, Capaldi A, Donadio M, Minischetti M, Salomone A, Vietti-Ramus G, Alabiso O, Aglietta M: Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: A pilot phase II study. Am J Clin Onco126:95-97, 2003. (Pubitemid 36205905)
17. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001. (Pubitemid 32441378)
18. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander R J, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis M J, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Onco121:2889-2895, 2003. (Pubitemid 46621838)
19. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Onco120:1215-1221, 2002. (Pubitemid 34177427)
20. Winer EP, Burstein HJ: New combinations with Herceptin in metastatic breast cancer. Oncology 61:50-57, 2001. (Pubitemid 33033425)
21. Gianni L: The future of targeted therapy: Combining novel agents. Oncology 63:47-56, 2002.
22. Bell R: Ongoing trials with trastuzumab in metastatic breast cancer. Ann Oncol 12:69-73, 2001.
23. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon D J: Phase II study of receptorenhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.J Clin Onco116:2659-2671, 1998. (Pubitemid 28363029)
24. Crown J, Pegram M: Platinum-taxane combinations in metastatic breast cancer: An evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat 79:Sl1-18, 2003.
25. O'Shaughnessy J, Blum J, Moiseyenko V, Jones S, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger H, Laws S: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5.fluorouracil) as first-line therapy for advanced/ metastatic breast cancer. Ann Oncol 12:1247-1254, 2001. (Pubitemid 32994752)
26. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui W, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard, R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase Ill trial results. J Clin Onco120:2812-2823, 2002. (Pubitemid 34651510)
27. Meza L, Amin B, Horsey M: A phase II study of capecitabine in combination with Paclitaxel as first or second line therapy in patients with metastatic breast cancer. Proc Am Soc Clin Onocol 21, 70b (abstract2029), 2001.
28. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y: Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/ 5'-dFUrd in human breast cancer models. Cancer Chernother Pharrnaco14 9:211-216, 2002. (Pubitemid 34185594)
29. Tan-Chiu E Piccart M: Moving forward: Herceptin in the adjuvant setting. Oneology 63:57-63, 2002.
30. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N: Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854, 2002. (Pubitemid 34705057)
31. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA: Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94:855-857, 2002. (Pubitemid 34705058)
32. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120:1713-1719, 2001. (Pubitemid 32523489)
33. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95:1825-1833, 2003. (Pubitemid 38054683)
34. Normanno N, Campiglio M, De IA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon D; Menard S: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65-72, 2002. (Pubitemid 34436727)
35. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Onco121:2787-2799, 2003. (Pubitemid 46606324)
36. Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL: Combined modality radioimmunotherapy. Promise and peril. Cancer 94:1320-1331, 2002. (Pubitemid 34150896)
37. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000. (Pubitemid 30106623)
38. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK: Epidermal growth factor receptortargeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204-1213, 2001. (Pubitemid 32708671)
39. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowser M, Workman P, Johnston SR: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor Rl15777 in human breast cancer. Clin CancerRes 7:3544-3550, 2001. (Pubitemid 33069993)
40. Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A: Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, Rl15777, in advanced breast cancer. J Clin Onco121:2492-2499, 2003. (Pubitemid 46606330)
41. Hidalgo M, Rowinsky EK: Rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19:6680-6686, 2000. (Pubitemid 32197708)
42. Mita MM, Mita A, Rowinsky EK: Mammalian target of rapamycin: A new molecular target for breast cancer. Clin Breast Cancer 4:126-137, 2003. (Pubitemid 36939419)
43. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski, MX: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002. (Pubitemid 41039113)
44. Albanell J, Codony J, Rovira A, Mellado B, Gascon, P: Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Bio1532:253-268, 2003. (Pubitemid 37176793)
45. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Allgood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K: The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res 61:7196-7203, 2001. (Pubitemid 32946515)
46. Xia W, Mullin RJ, Keith BR, Hu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL: Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erkl/2 and AKT pathways. Oncogene 21:6255-6263, 2002.
47. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW: Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Sernin Onco129:11-21, 2002. (Pubitemid 34816061)
48. Stathopoulos GP: Characterization as a target for cancer therapy in relation to orphan status disorders. Oncol Rep 9:1257-1259, 2002.
49. Nahta R, Esteva FJ, Trent S, Yang C, Schmidt EV, Hortobagyi GN, Iglehart JD, Kempkes B: In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemother Pharmacol 53:186-190, 2004. (Pubitemid 38186999)
50. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 21:46-53, 2003.